Chinese biotech developing plant-based (rice) recombinant human serum albumin and other recombinant proteins.
Chinese biotech developing plant-based (rice) recombinant human serum albumin and other recombinant proteins.
In one line: A niche plant-made-biologics company.
Moat: narrow (IP / patents, process know-how). Proprietary rice-seed bioreactor platform for producing recombinant albumin, a novel manufacturing route.
Headquarters: Wuhan, China · Employees: 253
Size Wuhan Healthgen Biotechnology (688765.SS) is a China Health Care company (Biotechnology) with a market value of $1.46B, the 1556th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥28.23 on 18 Nov 2026.
Performance Over six months the shares fell 50.7%, against -17.0% for the median peer and -20.0% for the China market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 89.8% over the last twelve months (peer median +20.3%); the operating margin is -297.1% (peer median -12.4%).
Valuation It trades at 205.0× enterprise value to sales against a peer median of 12.9× (5th most expensive of 17).
Capital Return on invested capital runs 15.4 points below its cost of capital (11.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | CN¥47.9M | CN¥25.2M | CN¥22.4M | CN¥12.6M |
| Revenue growth | — | +90% | +12% | +78% | — |
| Gross profit | n/a | -CN¥33.2M | -CN¥38.3M | -CN¥28.3M | -CN¥2.55M |
| EBITDA | n/a | -CN¥75.9M | -CN¥105M | -CN¥160M | -CN¥150M |
| Net income | n/a | -CN¥157M | -CN¥151M | -CN¥187M | -CN¥144M |
| Free cash flow | n/a | -CN¥666M | -CN¥220M | -CN¥224M | -CN¥425M |
| Capital expenditure | n/a | CN¥538M | CN¥167M | CN¥102M | CN¥358M |
| Total debt | CN¥369M | CN¥368M | CN¥223M | CN¥93.9M | CN¥15.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Wuhan Healthgen Biotechnology 688765.SS | $1.46B | -51% | +90% | -297% | 205.0× | n/a |
| Shanghai RAAS Blood Products 002252.SZ | $4.57B | -15% | -22% | 17% | 5.4× | n/a |
| Hualan Biological Engineering 002007.SZ | $3.20B | -17% | -11% | 17% | 5.3× | 15.8% |
| CSL CSL.AX | $63.7B | +102% | -2% | 26% | 4.8× | 6.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688765.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.7% | -10.2% | 10th lowest of 21 |
| 6-month return | -50.7% | -17.0% | 2nd lowest of 20 |
| Distance from 52-week high | -78.1% | -45.9% | 2nd lowest of 21 |
| Revenue growth (TTM) | +89.8% | +20.3% | 6th highest of 17 |
| Operating margin | -297.1% | -12.4% | 7th lowest of 18 |
| EV / Sales | 205.0× | 12.9× | 5th most expensive of 17 |
| ROIC minus cost of capital | -15.4 pp | -14.4 pp | 6th highest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.53B | -41% | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.53B | 0% | +2,388% | 21% | 10.1× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.54B | -14% | +739% | 41% | 0.8× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |